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Abstract
 
Antigenic variation is a strategy exploited by influenza viruses to promote survival in the face of
the host adaptive immune response and constitutes a major obstacle to efficient vaccine devel-
opment. Thus, variation in the surface glycoproteins hemagglutinin and neuraminidase is re-
flected by changes in susceptibility to antibody neutralization. This has led to the current view
that antibody-mediated selection of influenza A viruses constitutes the basis for annual influ-
enza epidemics and periodic pandemics. However, infection with this virus elicits a vigorous
protective CD8
 
1
 
 cytotoxic T lymphocyte (CTL) response, suggesting that CD8
 
1
 
 CTLs might
exert selection pressure on the virus. Studies with influenza A virus–infected transgenic mice
bearing a T cell receptor (TCR) specific for viral nucleoprotein reveal that virus reemergence
and persistence occurs weeks after the acute infection has apparently been controlled. The per-
sisting virus is no longer recognized by CTLs, indicating that amino acid changes in the major
viral nucleoprotein CTL epitope can be rapidly accumulated in vivo. These mutations lead to a
total or partial loss of recognition by polyclonal CTLs by affecting presentation of viral peptide
by class I major histocompatibility complex (MHC) molecules, or by interfering with TCR
recognition of the mutant peptide–MHC complex. These data illustrate the distinct features of
pulmonary immunity in selection of CTL escape variants. The likelihood of emergence and
the biological impact of CTL escape variants on the clinical outcome of influenza pneumonia
in an immunocompetent host, which is relevant for the design of preventive vaccines against
this and other respiratory viral infections, are discussed.
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Introduction
 
In the adaptive immune response to most viruses, both T
cells and neutralizing antibody play complementary roles in
eliminating virus and promoting recovery (1, 2). During
viral infections, the host aims to eliminate the virus and
minimize associated pathology, whereas viruses have devel-
oped a remarkable variety of means to circumvent or sup-
press host responses to allow persistence and dissemination
to new hosts over extended time periods (for reviews, see
references 2–9). While many DNA viruses have acquired
host genes that interfere with the immune response, for ex-
ample pox and herpes viruses (8, 10, 11), RNA viruses
cannot tolerate a large genome because of the low fidelity
inherent to RNA replication, and as a consequence, rely
on other means, such as rapid variation, to survive and per-
sist. Thus, genetic variation is a major strategy exploited by
viruses to evade host immune pressure and constitutes a
major obstacle to efficient vaccine development. Variation
occurs by several different mechanisms, including muta-
tion, recombination, and reassortment for viruses with a
segmented genome, and different virus families utilize these
to different extents. As a result, RNA viruses exist as com-
plex, dynamic mixtures of heterogeneous populations,
termed quasispecies (12). If a virus is replicating under a
constant set of environmental conditions, the consensus se-
quence of the viral population will remain unchanged.
However, if conditions alter, for example under selective
pressure of the host immune response, mutations that con-
fer an increase in fitness (the relative ability of the virus to
produce infectious progeny) will be selected for and come
to predominate in the viral population.
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Influenza A viruses have a single-stranded, segmented
negative sense RNA genome characterized by its high de-
gree of variability and the ability to cause acute respiratory
infections of humans and animals, often resulting in signifi-
cant morbidity and mortality (13, 14). A large body of ex-
perimental evidence suggests an essential role for neutraliz-
ing antibodies and CD8
 
1
 
 CTLs in eliminating influenza
virus and promoting recovery of the host (1, 15–20). Al-
though vigorous antibody responses directed against the
surface glycoproteins hemagglutinin (HA)
 
1
 
 and, to a lesser
extent, neuraminidase are generated against the virus,
cross-protective humoral immunity against multiple virus
strains does not occur due to the inherent antigenic vari-
ability of these proteins (21–24). This allows sequential re-
infection of individuals over successive years by influenza
viruses bearing antigenically distinct surface glycoproteins.
Influenza virus variation involves antigenic “shift and
drift.” Antigenic “shift” may be brought about by reassort-
ment of viral genes, due to the segmented nature of the in-
fluenza virus genome, whereas antigenic “drift” occurs
within HA and neuraminidase subtypes, and involves accu-
mulation of minor genetic changes (usually point muta-
tions; for reviews, see references 13, 25–27). Evidence for
the role of humoral immunity in selection of variants of in-
fluenza virus surface proteins is overwhelming, with evolu-
tion of viral surface proteins occurring along a single lin-
eage defined by accumulation of amino acid substitutions
in neutralizing antibody target sites on HA, largely within
the HA1 subdomain. In marked contrast to the subtype
specificity of B cell, and thus antibody, recognition, human
and murine MHC class I–restricted CD8
 
1
 
 CTL responses
are usually cross-reactive between subtypes of influenza vi-
rus (15, 19, 28, 29). Consistent with this cross-reactivity is
the relative conservation of the dominant CTL target anti-
gens, usually internal viral proteins that are expressed early
in infected cells, before progeny virus release, and are inac-
cessible to antibody selection pressure.
The current consensus is that the acute nature of in-
fluenza A virus infection is unlikely to allow oscillations
of CTL epitopes. However, the observations in this re-
port, using mice transgenic for an influenza nucleoprotein
(NP)
 
366–374
 
 peptide–specific TCR, demonstrate selection of
CTL escape variants of influenza virus. Thus, CD8
 
1
 
 CTL
responses directed to an internal viral protein can exert se-
lective pressure on the virus, and variants containing point
mutations in the NP
 
366–374
 
 epitope readily emerge. These
mutations permit infected cells not only to escape trans-
genic CTL attack by interfering with TCR recognition of
the mutant peptide–MHC complex, but surprisingly, also
allow escape from polyclonal CTL recognition by affecting
peptide binding to MHC class I. Such mutations facilitate
viral reemergence and persistence, which occur weeks after
the acute viral infection has apparently been resolved. The
 
data demonstrate that amino acid substitutions in the major
viral NP CTL epitope can be rapidly generated and se-
lected in vivo. In addition, this highlights possible limita-
tions of vaccination strategies based on enhancement and
acceleration of virus-specific CD8
 
1
 
 CTL responses in in-
fluenza pneumonia.
 
Materials and Methods
 
Mice and Virus Infection.
 
F5 transgenic mice expressing a TCR
specific for influenza peptide NP
 
366-374
 
 (30, 31), F5 mice with a
targeted mutation of recombination activating gene 1 (F5-RAG-
1
 
2/2
 
) (32, 33), and RAG-1
 
2/2
 
 mice were provided by Dr. D.
Kioussis (National Institute of Medical Research, London, UK).
Animals were bred and maintained in a pathogen-free environ-
ment. All procedures involving mice were conducted in strict ac-
cordance with institutional guidelines for animal care. For infec-
tion, animals were anesthesized with methoxyflurane (Metofane;
Pitman-Moore) and inoculated intranasally with 50 
 
m
 
l of differ-
ent influenza virus doses diluted in PBS containing 0.1% BSA.
 
Viruses.
 
Influenza virus strain A/Memphis/102/72 (H3N2)
was obtained from Dr. J.J. Skehel (National Institute of Medical
Research, London, UK). Viruses were propagated in 10 d–embry-
onated hen eggs, and virus titers were determined by plaque assay
using Madin-Darby canine kidney (MDCK) cells as described
previously (34). Isolates of influenza A virus derived from lungs of
infected mice were cloned by three rounds of plaque purification
and propagated on MDCK cells.
 
Virus Titers in Lung Tissue.
 
Tissues from infected mice were
homogenized in 1 ml of cold PBS, and 50 
 
m
 
l of log dilutions of
clarified homogenates were adsorbed for 1 h at 37
 
8
 
C onto con-
fluent monolayers of MDCK cells in 96-well plates. Infected
monolayers were then overlaid with MEM supplemented with
0.5% BSA and tosylamido-phenylethyl-chloromethyl ketone
(TPCK)-trypsin (250 
 
m
 
g/ml; Sigma-Aldrich) and incubated for
72 h at 37
 
8
 
C and 5% CO
 
2
 
. Virus growth was assessed by HA as-
say with 1% chicken erythrocytes. 50% tissue culture infectious
dose (TCID
 
50
 
) was determined by the method of moving aver-
ages (35), and virus titers are expressed as TCID
 
50
 
/g tissue. The
threshold of virus detection in the MDCK assay is 
 
z
 
10
 
2
 
 TCID
 
50
 
/g
lung tissue.
 
Viral Peptides.
 
Peptides were synthesized at the Medical Col-
lege of Georgia Molecular Biology Core Facility, using a Perkin-
Elmer 433A peptide synthesizer. The peptides used in this study
were the H-2D
 
b
 
–binding viral peptide NP
 
366-374
 
 (ASNENM-
DTM) of A/Memphis/102/72 or its CTL escape variants NP
 
370S
 
(ASNESMDTM), NP
 
370D
 
 (ASNEDMDTM), NP
 
370T
 
 (ASNET-
MDTM), NP
 
374T
 
 (ASNENMDTT), NP
 
371I
 
 (ASNENIDTM),
and the H-2K
 
b
 
–binding influenza virus peptide nonstructural
protein 2 (NS2)
 
114–121
 
 (RTFSFQLI) (36).
 
Cytotoxicity Assay.
 
Cell-mediated cytotoxicity was deter-
mined in a standard 5-h microcytotoxicity test as described (32,
37). EL-4 (H-2
 
b
 
) cells infected with virus or loaded with peptide
were used as target cells. To generate virus-infected target cells,
EL-4 cells were washed in serum-free medium, and virus at a
multiplicity of infection of 5 was added at the time of 
 
51
 
Cr label-
ing. Effector cells were in vitro activated day 4 transgenic CTLs
or polyclonal CTLs specific for epitope NP
 
366-374
 
 or NS2
 
114–121
 
 of
A/Memphis/102/72. Naive transgenic CTLs were stimulated at
a density of 10
 
5
 
, together with NP
 
366-374
 
 or NS2
 
114–121
 
 peptide-
pulsed (0.1 
 
m
 
g/ml) irradiated (30 Gy) splenocytes (4 
 
3
 
 10
 
6
 
) in 2
ml of IMDM (GIBCO BRL) supplemented with 10% FCS and
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; HA, hemag-
glutinin; MDCK, Madin-Darby canine kidney; NP, nucleoprotein; NS2,
nonstructural protein 2; RAG, recombination activating gene; TCID
 
50
 
,
50% tissue culture infectious dose. 
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10 U/ml of murine recombinant IL-2. Polyclonal CTLs specific
for the viral epitope NP
 
366-374
 
 or NS2
 
114–121
 
 were obtained by re-
stimulation of memory spleen cells from infected C57BL/10
mice after several cycles (every 7–10 d) with 
 
g
 
-irradiated spleno-
cytes loaded with the corresponding peptide.
 
Stabilization of H-2D
 
b 
 
Complexes on RMA-S Cells by Synthetic
Peptides.
 
For stabilization assay, RMA-S cells were grown at
25
 
8
 
C (5% CO
 
2
 
) for a minimum of 24 h to induce stable H-2D
 
b
 
expression at the cell surface (38–40). 10
 
5 
 
cells were mixed with
varying concentrations of peptide in 100 
 
m
 
l IMDM medium con-
taining 10% FCS, and then incubated in microtiter plates for 30
min at 25
 
8
 
C, followed by 4 h at 37
 
8
 
C. Cell surface expression of
H-2D
 
b
 
 was determined using the H-2D
 
b
 
–specific mouse mAb
(B22-249; provided by Dr. U. Hämmerling, Sloan-Kettering
Cancer Center, New York, NY), and FITC–conjugated goat
anti–mouse IgG secondary antibody (Jackson ImmunoResearch
Laboratories). Cells were analyzed with a FACSCalibur™ flow
cytometer (Becton Dickinson). For negative controls, samples
were incubated in the absence of peptide or in the absence of the
primary antibody.
 
Quantitative Analysis of Virus-specific CD8
 
1 
 
T Cells in the Pneu-
monic Lung and Spleen.
 
MHC–peptide tetramers for staining of
epitope-specific T cells were prepared as described previously
(41–44). In brief, soluble MHC class I (H-2D
 
b
 
 or H-2K
 
b
 
) with a
specific biotinylation site and human 
 
b
 
2-microglobulin were
produced in large amounts as recombinant proteins by transform-
ing 
 
Escherichia coli
 
 strain BL21 (DE3) with the plasmids pET23-
D
 
b
 
-BSP, pET23-K
 
b
 
-BSP, or pHN1-
 
b
 
2m (provided by Dr. J.D.
Altman, Emory University, Atlanta, GA), respectively. Expres-
sion of the proteins was induced with isopropyl-
 
b
 
-thiogalactopy-
ranoside as described (41). Folding, purification, and biotinylation
of H2-D
 
b
 
 and -K
 
b
 
 peptide complexes were performed as de-
scribed (42). Finally, biotinylated MHC–peptide complexes were
tetramerized by addition of PE-conjugated streptavidin (Molecu-
lar Probes). Experiments used H-2D
 
b
 
 complexed with A/Mem-
phis/102/72 NP
 
366–374
 
 peptide or H-2K
 
b
 
 complexed with
NS2
 
114–121
 
 peptide. Bronchoalveolar lavage (BAL) cells or single
cell suspensions prepared from spleen were stained in PBS con-
taining 2% BSA and 1% NaN
 
3 
 
directly with FITC- or PE-cou-
pled reagents or indirectly with biotinylated antibodies, followed
by streptavidin-Tricolor (Caltag). After staining for 1 h at 4
 
8
 
C,
cells were fixed in PBS containing 2% paraformaldehyde and ana-
lyzed with a FACSCalibur™. mAbs were against mouse CD8
(clone 53-6.7), CD4 (clone GK1.5), TCR V
 
b
 
11 (clone KT11),
CD44 (clone IM-7), and L-selectin (clone MEL-14). The anti-
bodies were prepared from hybridoma cell lines or purchased
from BD PharMingen.
 
Intracellular Staining for IFN-
 
g
 
 after Peptide Stimulation.
 
Cell
populations recovered by BAL or from spleen were cultured in
96-well U-bottomed plates at 4 
 
3
 
 10
 
6
 
 cells/well in 200 
 
m
 
l RPMI
1640 (GIBCO BRL) supplemented with 10% FCS, 10 U/well
murine IL-2, and 1 
 
m
 
g/well brefeldin A (BD PharMingen) in the
presence or absence of NP
 
366–374
 
 or NS2
 
114–121
 
 CTL epitope pep-
tide at a concentration of 1 
 
m
 
g/ml (43, 44). After 6 h of culture,
cells were harvested, washed once in FACS
 
®
 
 buffer (PBS with 1%
BSA and 0.2% sodium azide), and surface stained with PE–conju-
gated rat mAb specific to mouse CD8
 
a
 
 (clone 53-6-72). After
washing, cells were stained for intracellular cytokines using the
Cytofix/Cytoperm kit (BD PharMingen) according to the manu-
facturer’s instructions. FITC-conjugated rat mAbs specific to mu-
rine IFN-
 
g
 
 or TNF-
 
a
 
 (clones XMG1.2 and MP6-XT22, respec-
tively; Caltag), and its isotype control antibody (rat IgG1 and
IgG2a, respectively) were used to identify cytokine-positive cells.
 
Stained cells were washed an additional time and fixed in PBS
containing 0.1% paraformaldehyde. Samples were acquired on a
FACSCalibur™ flow cytometer (Becton Dickinson), and data
were analyzed using CELLQuest™ software.
 
Proliferation of T Cells in Response to Peptide Stimulation.
 
Sple-
nocytes from F5 transgenic mice (5 
 
3
 
 10
 
5
 
/well) or F5-RAG-1
 
2/2
 
mice (5 
 
3
 
 10
 
4 
 
/well) were cultured with irradiated (30 Gy) sple-
nocytes (5 
 
3
 
 10
 
5
 
/well) from C57BL/10 mice in the given con-
centrations of peptides in IMDM for 72 h. Proliferation of T cells
was determined by incorporation of [
 
3
 
H]thymidine (1 
 
m
 
Ci/well)
during the last 6–8 h of culture.
 
Sequence Analysis of Viruses.
 
Virus in the supernatant from in-
fected MDCK cells at 48 h after infection at multiplicity of infec-
tion 0.01 was precipitated in an equal volume of LiCl (3 M) and
urea (6 M) by centrifugation (20,000 
 
g
 
, 15 min). Viral RNA was
isolated by digestion with proteinase K, phenol-chloroform ex-
traction, and precipitation with sodium acetate and ethanol. Viral
RNA (1 
 
m
 
g) was then used as a template for DNA synthesis by
reverse transcriptase (Moloney murine leukemia virus; GIBCO
BRL) using the manufacturer’s instructions and a primer (5
 
9
 
-AG-
CAAAAGCAGG-3
 
9
 
) binding the conserved 3
 
9
 
 of influenza viral
RNA segments. One fifth of the cDNA mixture was amplified
by PCR using 2.5 U of Pfu polymerase (Stratagene) according to
the manufacturer’s instructions in a final volume of 50 
 
m
 
l with
the primer pair 5
 
9
 
-GGAATTCAATCAGACCGAACGAGAA-
3
 
9
 
, complementary to nucleotides 990–1007, and 5
 
9
 
-GGAAT-
TCCCATGATGGTTGGTTTGT-3
 
9
 
, complementary to nucle-
otides 1324–1307 of NP of A/Memphis/102/72. PCR ran for
30 cycles using the following conditions: denaturation was for 0.5
min at 94
 
8
 
C, annealing for 0.5 min at 55
 
8
 
C, and extension for 1
min at 72
 
8
 
C. The amplified 440-bp fragment was purified using a
QIAquick PCR purification kit (Qiagen) and subjected to DNA
sequencing using the primers described above and a Dye Termi-
nator Cycle Sequencing kit (PerkinElmer). The sequencing
product was analyzed on an automated DNA sequencer (model
377; PerkinElmer).
 
Results
 
Reemergence and Persistence of Influenza A Virus in F5-
RAG-1
 
2/2
 
 Mice. The CD81 CTL response in F5-RAG-
12/2 mice infected with 102 PFU of A/Memphis/102/72
promotes rapid reduction of pulmonary virus to below the
limit of detection by TCID50, by days 6–8 after infection,
and the mice initially recover from primary viral pneumo-
nia. However, if mice are left for a sufficient period (z60
d), they eventually sicken and die. This late mortality is as-
sociated with virus reemergence by days 20–24 and viral
persistence in the lung for several weeks (Fig. 1). As virus
control in F5-RAG-12/2 mice is mediated solely via CD81
CTLs arriving in the infected respiratory tract 2–3 d after
peak lung viral titers (Fig. 1), this novel finding raised the
possibility that A/Memphis/102/72 variants escaping im-
mune recognition by transgenic CTLs had been selected, as
initially shown for lymphocytic choriomeningitis virus (45).
Level of Virus Inoculum Influences the Range of Influenza Vi-
rus Variants. To verify that virus reemergence was due to
lack of recognition by transgenic CTLs, virus recovered
from lungs of A/Memphis/102/72-infected (102 PFU) F5-
RAG-12/2 mice on days 4, 6, 20, 34, and 50 after infection
was analyzed directly in a 51Cr-release assay with the fol-1856 CD81 CTL Escape Variants in Influenza Virus Pneumonia
lowing results: EL-4 (H-2b) target cells infected with bulk
virus isolated on days 4 and 6 after infection, but not on
days 22, 34, or 50, were sensitive to lysis by in vitro–acti-
vated transgenic CTLs at comparable levels to target cells
infected with wild-type virus. In contrast, the same target
cells were lysed efficiently by polyclonal CTLs specific to
NP366–374 or by CTLs specific to the NS2114–121 epitopes of
A/Memphis/102/72 used as a control to verify appropriate
infection of target cells in the assays (Fig. 2). These results
were confirmed with plaque-purified isolates from mice in-
fected 22 and 34 d previously (data not shown).
To ascertain that loss of CTL recognition was associated
with viral genotype changes, we derived sequences corre-
sponding to a region within the A/Memphis/102/72 NP
gene (nucleotides 990–1307) comprising the NP366–374
CTL epitope. Virus recovered from lungs of infected mice
(three per group) on days 4 and 6 did not show any nucle-
otide difference in the analyzed NP gene fragment. How-
ever, virus resistant to CTL lysis recovered from mice
killed on days 22 and 34 after infection revealed identical
results, indicating predominance of one virus variant type,
containing an amino acid change (371M®I) at position 6
(the transgenic TCR recognition site) within the NP366–374
epitope. Sequencing plaque-purified isolates (five per virus
sample) gave identical results (data not shown), confirming
rapid in vivo selection of virus variants resistant to lysis
by transgenic CTLs but still recognized by polyclonal
NP366–374–specific CTLs. Note that in vitro–restimulated
polyclonal NP-specific CTLs from C57BL/6 mice contain
a mixture of individual clonotypes, at least some of which
will be cross-reactive between wild-type and peptide-
bearing alterations at TCR contact residues (as shown in
Fig. 2).
Next, the influence of virus inoculum on the frequency
and spectrum of variant type in the reemergent virus was
studied. Infection of transgenic mice with increasing doses
of A/Memphis/102/72 (103–106 PFU) resulted in higher
virus titers on days 2–4 and accelerated kinetics of virus re-
emergence in the lung. Thus, emergent virus was detected
earlier in mice infected with 104 PFU (day 18) than with
102 PFU (day 22). Analysis of lung virus isolates derived
from mice infected 20 or 34 d previously revealed a pure
population of CTL escape variants. Approximately half (15
of 35 total) of virus isolates recovered from mice after in-
fection with relatively high doses (104 to 106 PFU) of A/
Memphis/102/72 either sensitized target cell lysis by poly-
clonal NP366–374 peptide–specific CTLs to a lesser degree
than wild-type A/Memphis/102/72, or were unable to
sensitize target cell lysis at all (data not shown). The re-
mainder of the isolates displayed the phenotype of the vari-
ants found in mice infected with 102 PFU, as they were
unable to sensitize target cell lysis by transgenic cells but
were still recognized by polyclonal CTLs.
Figure 1. Recurrence and persistence of A/
Memphis/102/72 virus in F5-RAG-12/2 mice.
Mice were infected with 102 PFU, and virus ti-
ters were expressed as mean log10 TCID50 per
gram of lung of three to five mice (d). The ki-
netics of transgenic cells in the BAL is indicated
as mean log10 6 SEM of three mice (s).
Figure 2. Selection and propagation of CTL escape variants in F5-
RAG-12/2 mice infected with a low dose of A/Memphis/102/72. EL-4
(H-2Db) target cells infected with A/Memphis/102/72 or virus recovered
at the indicated times from lungs of infected (102 PFU) F5-RAG-12/2
mice were analyzed directly in a 51Cr-release assay using in vitro–activated,
transgenic CTLs (m), polyclonal NP364–374 (d), or NS2114–121 (j) specific
CTLs. Lysis of uninfected target cells was ,5% at the highest E/T cell ra-
tio. Similar results were obtained in at least five separate experiments.1857 Price et al.
Sequence analysis of these isolates revealed two patterns
of mutation within the NP366–374 CTL epitope. The 15 iso-
lates that resisted lysis by polyclonal CTLs displayed al-
terations to dominant anchor residues at position 5 or 9
within the NP366–374 CTL epitope (370N®S, 370N®D,
370N®T, or 374M®T). An equal number (15 of 35 total
isolates) that sensitized target cells to lysis by polyclonal but
not by transgenic CTLs displayed a single mutation at resi-
due 6 or 7 (371M®I, 371M®V, 371M®T, or 372D®E)
that comes into direct contact with the TCR. The remain-
ing five isolates contained a mixture of two virus popula-
tions, with mutations 370N®S or 370N®T coexisting
with 371M®I. Isolates containing double mutations were
not obtained. This propensity for mutation was specific for
the sequence of CTL epitope NP366–374, as no other changes
were observed in the z150 nucleotides flanking the epitope
on each side. These results are summarized in Table I.
Presentation and CTL Recognition of the NP366–374 Epitope of
Influenza CTL Escape Variants. For further analysis, triple
plaque-purified isolates were obtained for each of the vari-
ant types with a substitution in the NP366–374 peptide an-
chor residue at position 5 or 9 (designated A/Mem/NP370S,
A/Mem/NP370D, A/Mem/NP370T, or A/Mem/NP374T),
and for the main variant type with a substitution in the
TCR contact site at position 6 (A/Mem/NP371I). To de-
termine whether the changes within the NP366–374 epitope
affect presentation of the peptide by MHC molecules or af-
fect recognition by specific CTLs, we synthesized peptides
corresponding to the NP366–374 variant epitope sequences
and assayed them for their ability to bind H-2Db molecules
(RMA-S H-2Db stabilization assay and soluble MHC–pep-
tide binding assay). In addition, virus isolates and the corre-
sponding mutant peptides were assayed for their ability to
sensitize cells for lysis by in vitro–activated transgenic or
polyclonal NP366–374–specific CTLs.
RMA-S cells lack a functional transporter associated
with antigen processing (TAP)-2 gene, and express empty
H-2b molecules that can be stabilized by adding exogenous
peptide (39). The ability of a peptide to stabilize the MHC
molecule on the cell surface correlates with its affinity for
the molecule. The results in Fig. 3 show that the NP366–374
peptide of A/Mem/NP371I and wild-type viruses were
comparable in stabilizing the H-2Db molecule. In repeated
assays, the peptide of A/Mem/NP374T was found to stabi-
lize H-2Db expression slightly less well than for wild-type
peptide (z10-fold more variant peptide is required for
half-maximal stabilization than that of wild-type peptide).
In contrast, the mutations in the NP366–374 peptide of A/
Table I. CTL Escape Variants Displaying Point Mutations in the NP366–374 Epitope of A/Memphis/102/72 Influenza Virus
Virus isolate Nucleotide and deduced amino acid sequences Number of variant 
isolates/total tested
ASNEN M DTM
A/Memphis/102/72 GCT TCA AAT GAA AAC ATG GAT ACT ATG 0/35
S
A/Mem/NP370S --- --- --- --- AGC --- --- --- --- 3/35
D
A/Mem/NP370D --- --- --- --- GAC --- --- --- --- 2/35
T
A/Mem/NP370T --- --- --- --- ACC --- --- --- --- 8/35
T
A/Mem/NP374T --- --- --- --- --- --- --- --- ACG 2/35
I
A/Mem/NP371I --- --- --- --- --- ATA/T --- --- --- 18/35 (8/8)*
V
A/Mem/NP371V --- --- --- --- --- GTG --- --- --- 1/35
T
A/Mem/NP371T --- --- --- --- --- ACG --- --- --- 1/35
E
A/Mem/NP372E --- --- --- --- --- --- GAG --- --- 2/35
The nucleotide and deduced amino acid sequence of the NP366–374 epitope of wild-type and reemergent escape variants recovered from the lungs of
F5-RAG-12/2 mice that were infected with relatively high dose (104–106 PFU) of A/Memphis/102/72 are indicated. The nucleotide sequence is
given in viral sense, and differences in nucleotide or amino acid sequence are indicated in bold. The fraction of virus isolates displaying mutation
within the NP366–374 CTL epitope was compared with the number of analyzed isolates.
*In addition, the pattern of mutation of isolates recovered from lungs of mice that were infected with a relatively low dose of virus (102 PFU) was
analyzed, revealing one type of mutation, and is indicated in parenthesis. To avoid artifact, four DNAs derived from two independent PCR ampli-
fications, utilizing the high fidelity Pfu polymerase, were sequenced for each virus variant, with the same results.1858 CD81 CTL Escape Variants in Influenza Virus Pneumonia
Mem/NP370S, A/Mem/NP370D, or A/Mem/NP370T have a
major effect on the ability of the peptide to stabilize H-2Db
at the surface of RMA-S cells. Thus, for half-maximal
H-2Db stabilization, z100-fold (370N®S),  z500-fold
(370N®D), or z10,000-fold (370N®T) more variant
peptide than wild-type was required. It should be noted
that the variant peptides stabilize a significantly lower level
of H-2Db at the highest concentration assayed compared
with the wild-type peptide. As an independent assay for
binding affinity, the concentration of the peptide yielding
50% inhibition (IC50) of the binding of the radiolabeled ad-
enovirus E1A analogue peptide (SGPSNTYPEI) to soluble
H-2Db was measured as described by Vitiello et al. (36).
The data confirmed the general peptide binding pattern
found in the RMA-S stabilization assay. Thus, wild-type
peptide bound with high affinity (IC50 6 nM), whereas the
corresponding values for variant peptide were: 77 nM
(374M®T), 118 nM (370N®S), 835 nM (370N®D), and
6,424 nM (370N®T). Variant peptide with change in the
TCR contact site (371M®I) bound very efficiently to
H-2Db (IC50 2 nM). Therefore, changes in the NP366–374
peptides of A/Mem/NP370D, A/Mem/NP370S, and A/Mem/
NP370T affect binding of the peptide to H-2Db molecules,
whereas the change in A/Mem/NP371I interferes with rec-
ognition by transgenic CTLs. The alteration 374M®T
moderately reduces the binding ability of the peptide to
H-2Db in the above assays.
EL-4 target cells infected with A/Memphis/102/72 or
its variants were assayed with in vitro–activated transgenic
or polyclonal CTLs (Fig. 4). Target cells infected with A/
Mem/NP371I were lysed efficiently, though to a lesser de-
gree than wild-type infected target cells, by polyclonal
CTLs, but no lysis with transgenic CTLs was detected. In
contrast, the same effector CTLs did not lyse target cells in-
fected with A/Mem/NP370S, A/Mem/NP370D, A/Mem/
NP370T, or A/Mem/NP374T. All infected target cells were
lysed to a similar degree by in vitro–activated polyclonal
CTLs specific to the H-2Kb–restricted NS2114–121 epitope
(36), which is conserved between the wild-type and vari-
ants (Fig. 4).
Ability of A/Memphis/102/72 Variant Viruses and Corre-
sponding NP366–374 Peptides to Induce Proliferative Responses of
F5 Transgenic Cells and Sensitize Target Cell Lysis by Virus-
specific CTLs. The proliferative response of naive spleno-
cytes isolated from F5-RAG-12/2 mice to variant virus and
the corresponding NP366–374 peptides was tested. As shown
in Fig. 5 A, the peptide of A/Memphis/102/72 induced
significant proliferation of transgenic T cells at a concentra-
tion of z1025 mg/ml (10 pM). Peptide of A/Mem/NP374T
virus showed a slightly reduced ability (z10-fold) to induce
proliferation of transgenic CTLs, whereas a drastically re-
duced proliferative capacity was noticed with peptides of A/
Mem/NP370S ( z250-fold), A/Mem/NP370D ( z500-fold),
or A/Mem/NP370T ( z5,000-fold). No proliferation with
the peptide of A/Mem/NP371I was detected at the highest
concentration tested (10 mg/ml). The approximate concen-
trations required for half-maximal proliferation are: wild-
type peptide, 0.3 nM; variant peptides 374M®T, 2 nM;
370N®S 70 nM; 370N®D, 150 nM; and 370N®T, 2
mM. In contrast, transgenic cells showed significant prolifer-
ative responses only when stimulated with A/Memphis/
102/72-infected splenocytes as APCs, but did not prolifer-
ate when stimulated with variant virus–infected splenocytes
(Fig. 5 B). This suggests that an insufficient MHC–peptide
ligand density for proliferative responses can be produced
Figure 3. Relative binding of variant peptides to H-2Db molecules on
the surface of RMA-S cells. The ability of the NP366–374 peptide of A/
Memphis/102/72 (d) or its variants: NP370S (m), NP370D (.), NP370T
(j), NP374T ( r), or NP371I ( s) to stabilize cell surface expression of
H-2Db molecule at 378C was determined in dose–response experiments.
Each peptide was analyzed in four independent experiments with similar
results. Data are shown as H-2Db stabilization indices calculated as mean
fluorescence increase in relation to the expression level of H-2Db in the
absence of peptide, as indicated by the dashed line.
Figure 4. Ability of the A/Memphis/102/72 variants to sensitize target
cells for lysis by in vitro–stimulated transgenic or by polyclonal NP366–374
peptide–specific CTLs. Susceptibility of EL-4 (H-2b) target cells infected
with the A/Memphis/102/72 or its variant viruses to lysis by transgenic
CTLs (m) or polyclonal CTLs specific to NP366–374 (d) or specific to
NS2114–121 peptide (h) was evaluated in a 4–5-h standard cytotoxicity as-
say. Lysis of untreated target cells was ,5% at the highest E/T cell ratio.
Results are representative of several experiments.1859 Price et al.
during infection, but that a response can be triggered if
enough peptide is given to presenting cells exogenously.
To test the efficiency of the variant NP366–374 peptides to
sensitize target cells for lysis, splenocytes from F5-RAG-12/2
mice were stimulated with the NP366–374 peptide of wild-
type virus and the specific CTLs generated were tested. As
shown in Fig. 5 C, the variant peptides 370N®S,
370N®D, 370N®T, or 374M®T used at a final concen-
tration of 10 mg/ml sensitize EL-4 target cells for lysis by
transgenic CTLs as well as wild-type peptide. However,
marked differences in dose–response were observed. In
general agreement with the proliferation studies as detailed
above, peptide with the mutation 374M®T sensitizes cells
for lysis slightly less efficiently (,10-fold) than wild-type
peptide, whereas at least 1,000-fold more variant peptide
370N®S or 370N®D, and 1,000,000-fold more 374N®T
were required to sensitize cell lysis. Approximate concen-
trations required for half-maximal lysis: wild-type peptide,
1 pM; variant peptides 374N®T, 10 pM; 370N®S or
370N®D, 1 nM; and 370N®T, 1-5 mM. Variant peptide
with mutation 371M®I did not sensitize cell lysis at all. In
addition, F5-cells efficiently lysed wild-type virus-infected
target cells, whereas no lysis was observed with the variant
viruses (Fig. 5 D).
Behavior of CTL Escape Variant Viruses in Transgenic
Mice. The ability of variant peptides to induce prolifera-
tive responses and sensitize target cell lysis, which occurs at
large peptide excess (.0.01 mg/ml) for peptides with mu-
tation 370N®S, 370N®D, 370N®T, or in the case of
374M®T, slightly less well than wild-type peptide, raises
the question of whether infection with the cognate viruses
could trigger a CTL response in vivo. Thus, the capacity of
variant viruses to escape recognition by transgenic or poly-
clonal CD81 CTLs specific for the NP366–374 epitope in
vivo was evaluated. In contrast to A/Memphis/102/72, the
same dose of variants (A/Mem/NP370S, A/Mem/NP370D,
A/Mem/NP370T, A/Mem/NP374T, or A/Mem/NP371I)
persist in the lung at comparably high titers in F5-RAG-12/2
mice over the time period examined (Fig. 6, top), indicat-
ing that variant viruses did not trigger an antiviral CTL
Figure 5. Responses of F5-RAG-12/2 transgenic cells to A/Memphis/
102/72 variant viruses and corresponding NP366–374 peptides. (A) T cell
proliferative responses to peptide. F5-RAG-12/2 spleen cells (105/well)
were stimulated with the given concentration of the appropriate peptide
for 3 d. Proliferation was determined by incorporation of [3H]thymidine
pulsed during the last 6 h of culture. Stimulation indices were calculated
in relation to proliferation in medium control, for NP366–374 peptide of A/
Memphis/102/72 (d) or its variants A/Mem/NP370S ( m), A/Mem/
NP370D ( .), A/Mem/NP370T ( j), A/Mem/NP374T (r), or A/Mem/
NP371I ( s). (B) Proliferative response to virus. Spleen cells from F5-
RAG-12/2 mice (5 3 104/well) were cultured with virally infected (5
PFU/cell) irradiated (30 Gy) splenocytes (5 3 105/well) from C57BL/10
mice for 96 h. T cell proliferation was determined as described above.
Bars A–F show proliferation of T cells with APCs infected with A/Mem-
phis/102/72, A/Mem/NP370S, A/Mem/NP370D, A/Mem/NP370T, A/
Mem/NP374T, or A/Mem/NP371I, respectively. (C) Susceptibility of EL-4
target cells pulsed with given concentrations of peptide to lysis by trans-
genic cells. EL-4 cells labeled with 51Cr were added to 96-well plates
containing the given concentration of peptides and incubated with F5-
RAG-12/2 splenocytes activated in vitro with 0.1 mg/ml of NP366–374
peptide of A/Memphis/102/72 for 4–5 h. E/T cell ratio was 30:1 for all
groups. Different peptides are indicated as in A. (D) Ability of variant vi-
ruses to sensitize target cell lysis by in vitro–activated transgenic T cells.
This experiment is performed as described under C using EL-4 cells in-
fected with the variants as target cells. Bars A–F represent target cells in-
fected with the virus type as indicated in B.
Figure 6. Replication of A/
Memphis/102/72 or its variant vi-
ruses in the lung of F5-RAG-12/2
or RAG-12/2 mice. F5-RAG-12/2
(top) or B10-RAG-12/2 (bottom)
mice were infected with 102 PFU of
the indicated viruses. Virus titers,
expressed as mean log10 TCID50 per
gram of lung, were determined at
the times indicated. Data points are
expressed as mean log10 6 SEM of
three to five mice.1860 CD81 CTL Escape Variants in Influenza Virus Pneumonia
response in these mice. Similarly, all strains persisted at
equally high levels in control RAG-12/2 mice, indicating
that mutations in the NP366–374 epitope confer no disadvan-
tage for viral replication in vivo (Fig. 6, bottom).
As engagement of TCRs by MHC–peptide complexes
initiates subsequent signal transduction events resulting in
cytotoxicity, cytokine secretion, and cell proliferation (46),
it is possible, as has been shown for altered peptide ligands,
that the variant viral peptides elicit some of the physiologi-
cal T cell responses associated with full antigen stimulation
while blocking the completion of others. Thus, it is possi-
ble in vivo that the variant NP366–374 peptides could induce
clonal expansion and maturation without triggering cy-
tolytic activity. To test this possibility, the recruitment and
functional state of transgenic T cells recovered by BAL
from F5-RAG-12/2 mice infected with 104 PFU of A/
Memphis/102/72, or its variants 9 d previously was stud-
ied. A/Memphis/102/72 infection triggered a rapid accu-
mulation of large numbers of activated effector transgenic
CTLs (CD44high and CD62Llow) in the lung. These CTLs
efficiently lysed target cells sensitized with the wild-type
NP366–374 peptide. In contrast, no transgenic T cells were
detectable in the BAL of mice infected with A/Mem/
NP370S, A/Mem/NP370D, A/Mem/NP370T, A/Mem/NP374T,
or A/Mem/NP371I viruses (Table II). Comparable results
were obtained when BAL cells obtained from mice in-
fected 16 d previously were tested (data not shown).
CTL Response against the Variant Viruses in Immunologically
Competent Mice. The results described above show that
mutations occurring in the NP366–374 epitope resulted in
loss of epitope–recognition by transgenic cells. However, if
these mutations are biologically significant, variant virus
should elicit partial or complete loss of recognition by
polyclonal NP366–374 epitope–specific CTLs. To determine
whether this is the case, the effectiveness of variant viruses
to induce a polyclonal CD81 CTL response specific to the
NP366–374 epitope in immunologically competent mice was
examined by determining the size of primary and second-
ary CD81 CTL responses in BAL and spleen of C57BL/6
mice after primary (day 14) or rechallenge (day 10) infec-
tion with A/Memphis/102/72 or its variants.
First, virus-specific polyclonal CD81 CTL responses
were quantified by direct visualization with MHC class I
tetramers complexed to A/Memphis/102/72 NP366–374
(wild-type) or NS2114–121 epitopes (Fig. 7). Consistent with
previous reports, significant numbers of NP366–374 peptide–
specific CTLs were detectable in BAL after primary infec-
tion with A/Memphis/102/72. This contrasts sharply with
the apparent lack of NP366–374–specific CTLs in mice in-
fected with A/Mem/NP370S, A/Mem/NP370D, A/Mem/
NP370T, or A/Mem/NP374T viruses. In mice infected with
A/Mem/NP371I, a reduced influx of NP366–374 peptide–spe-
cific CTLs into the BAL was seen (as described in detail be-
low). The different profiles of the NP366–374 peptide–spe-
cific CD81 T cell response to infection with the variants
could be accounted for by different viral characteristics
such as intrinsic growth potential or tissue tropism. This
possibility can be eliminated because primary or recall in-
fection with wild-type or variant viruses induced a similar
NS2114–121 peptide–specific CD81 T cell response (Fig. 7).
Comparable results were obtained after secondary chal-
lenge of mice with the same virus strain. Likewise, quanti-
tative analysis of spleen cells by staining with tetramers sup-
ports the above results. Finally, intracellular staining of
IFN-g expression in BAL or splenocytes stimulated with
the NP366–374 peptide of A/Memphis/102/72 or NS2114–121
peptide revealed similar percentages to the data obtained by
tetramer staining (data not shown). As an independent test
of functional activity, we measured the ability of spleno-
cytes to develop CTL activity towards both the NP366–374
Table II. Inflammatory Response in the BAL of F5-RAG-12/2 Mice Infected with CTL Escape Variants of A/Memphis/102/72 Influenza 
A Virus
Virus isolate Total BAL cells/mouse F5 Tg cells/lung
Percentage of ex vivo CTL activity
at F5 Tg E/T ratio:
50 16 6 2
3106 3106
A/Memphis/102/72 10.6 6 1.4 9.4 6 3.6 62 43 22 6
A/Mem/NP370S 8.9 6 3.8 ,0.1 ,5– ––
A/Mem/NP370D 22.4 6 9.3 ,0.1 ,5– ––
A/Mem/NP370T 2.1 6 0.8 ,0.1 ,5– ––
A/Mem/NP374T 5.3 6 1.6 ,0.1 ,5– ––
A/Mem/NP371I 5.6 6 2.4 ,0.1 ,5– ––
The numbers of inflammatory cells in BAL are indicated as mean log10 6 SEM per lung of three mice. Transgenic CTLs were detected in the same
samples by staining cells with antibodies specific for Vb11 and CD8 and analyzed by flow cytometry. Absolute numbers of transgenic CTLs were
calculated as percentage of transgenic positive cells by flow cytometry multiplied by total cell number. Populations ,0.1% were considered
nondetectable. In the same experiment, the CTL activity was evaluated in a 4–5-h standard cytotoxicity assay. Lysis of uninfected target cells was
,5% at the highest E/T ratio. Similar results were obtained in an additional experiment (data not shown). Tg, transgenic.1861 Price et al.
peptide of wild-type or variant virus (A/Mem/NP370S, A/
Mem/NP370D, A/Mem/NP370T, or A/Mem/NP374T) upon
stimulation in vitro. The CTL activity observed upon in
vitro restimulation of splenocytes from mice after primary
or secondary virus challenge correlates with the data from
tetramer staining or intracellular staining of IFN-g expres-
sion, indicating that mutations at position 5 or 9 of the
NP366–374 epitope result in complete loss of recognition by
CD81 CTLs specific for that epitope (Fig. 8).
As epitope variants with mutations on residues of TCR
contact sites can function as agonists or antagonists of anti-
gen-specific T cells, we sought to examine whether infec-
tion of mice with A/Mem/NP371I (main variant type
found in the population of reemergent virus) would impact
the polyclonal CTL response specific to NP366–374 epitope.
Infection with A/Mem/NP371I induced CD81 T cells
cross-reactive between wild-type and variant NP366–374
peptides, as detected with tetramers containing the NP366–374
of A/Memphis/102/72 or by measuring CTL activity to-
ward both wild-type or variant NP366–374 peptide in cul-
tures of splenocytes during primary or recall infection
(Figs. 7 and 8, and data not shown). This observation is in
agreement with previous reports that variation on residues
in contact with TCRs can induce cross-reactive CTLs (47,
48). However, a more detailed quantitative analysis of the
CTL response in the BAL demonstrated that the number
of cross-reactive CTLs, which comprise a small fraction of
the CTLs in wild-type infected mice, was dramatically re-
duced in A/Mem/NP371I-infected mice. To better under-
stand the ontogeny of the CTL population in these mice,
we measured the ability of CD81 T cells to initiate IFN-g
synthesis upon stimulation with the original (wild-type) or
variant peptide. Intracellular IFN-g staining of BAL cells
revealed induction of a T cell subpopulation cross-reactive
between the wild-type and variant peptide, as well as a
population specific for the variant peptide alone (data not
shown). In several experiments, we consistently found that
the total magnitude of the NP366–374 peptide–specific CTL
population differs greatly between wild-type and A/Mem/
NP371I infection (3–10-fold more specific CD81 T cells
were detected in mice infected with wild-type versus vari-
ant). This suggests that exposure of a host to variants with
substitutions on the TCR-exposed side can impair the
CTL response to the equivalent epitope. From these ex-
periments, we conclude that mutations in the NP366–374
epitope result in complete (mutation at anchor residue po-
Figure 7. Quantitation of virus-specific CD81 T
cells in the inflammatory BAL populations of C57BL/6
mice after primary infection with A/Memphis/102/72
or its variant viruses. C57BL/6 mice were infected
with 104 PFU of A/Memphis/102/72 or its variants
and 14 d later the BAL population collected from each
group of mice (n 5 3–5) was pooled. Cells were exam-
ined by flow cytometry after surface staining with anti-
body to CD8 and MHC tetramer containing the wild-
type virus NP366–374 (top) or the NS2114–121 peptide
(bottom). The numbers shown in each quadrant de-
note the percentage of BAL cells within the lympho-
cyte/lymphoblast gate. These results are representative
of more than three separate experiments.1862 CD81 CTL Escape Variants in Influenza Virus Pneumonia
sition 5 or 9) or partial (TCR contact residue at position 6)
loss of recognition by polyclonal CD81 T cells specific to
that epitope.
Discussion
Antigenic variation affecting recognition by antibody or
cytotoxic T cells is a strategy that viruses exploit to pro-
mote their survival in the face of the host adaptive immune
system (7, 38, 49, 50). Although virus variants that are not
recognized by epitope-specific CTLs have been shown to
arise during several viral infections, in many cases their sig-
nificance remains controversial. It has been argued that the
immune response is plastic enough to contain their replica-
tion, and that escape at one epitope is unlikely to give ma-
terial advantages to viral persistence because several CD81
T cell epitopes may be recognized simultaneously by CTLs
in an immunocompetent host. However, data derived from
more recent studies in several viral systems strongly suggest
that CTL escape plays a role in viral evolution, reinforcing
the concept that CTL escape variants generated during in-
fection may promote virus survival in the host (6, 7, 38, 49,
50). In line with this view, changes in CTL epitopes occur-
ring as a result of immune pressure would generate anti-
genic variants of biological significance when the ability of
the host to control viral infection is tenuous and their
emergence may tip the balance to the pathogen, resulting
in chronic infection. The lack of reported CTL escape
variant selection in influenza has been ascribed to the acute
nature of the infection and its confinement to the respira-
tory tract. In this regard, viruses that are known to be se-
lected to some degree by CD81 CTLs are thought to differ
regarding pathogenesis, mechanisms of persistence, and
mutation rates. However, the studies reported here suggest
that the respiratory tract can act as a suitable site for genera-
tion of CTL escape variants of influenza virus, albeit under
strong and highly directed selective pressure against an im-
munodominant epitope.
Here, transgenic CTLs in the absence of a virus-specific
antibody response are sufficient to reduce the viral load in
the lung below the threshold of detection by days 8–10 and
virus remains undetectable for a period of 2–3 wk. How-
ever, at the end of this period, virus that is resistant to CTL
recognition reemerges and persists at high titer in the lungs
for several weeks until the mice succumb to viral infection.
The time of viral reemergence and the repertoire of variant
populations depend on the initial dose of infection. Thus,
by increasing the dose of infection, virus reappears in the
lung earlier and a more diverse mutant population is ob-
served.
In general, the selection of CTL escape variants depends
on the strength of CTL pressure, the rate of viral turnover,
and the escape mutant fitness. In our model, the lung rep-
resents an ideal site for selection of CTL escape variants
because the virus has several days to become established in
the respiratory tract before CTLs appear at sites of virus
replication, producing a pool of virus that is a potential
source of variants. Influenza virus replication is substan-
tially restricted in vivo, as generation of infectious virus by
HA cleavage depends on a trypsin-like enzyme restricted
to the respiratory tract (51, 52). As a consequence, the vi-
rus-specific CTL response is targeted to the respiratory
tract and effector CTLs can reach extremely high frequen-
cies in the BAL. The selection process in a respiratory viral
infection profoundly differs from systemic infections where
virus replication occurs at the same site as the induction of
CTL responses. Thus, CTL-mediated pressure on the vi-
rus, in combination with other factors, is sufficient to lead
to selection of escape variants. Two hypotheses can be en-
visaged: either CTL escape mutants were present in the
initial viral inoculum and then selected, or they were gen-
erated during the ongoing infection and then selected un-
der CTL pressure. Our data favor the second hypothesis, as
bulk virus isolated on days 4 and 6 after infection was rec-
ognized efficiently by peptide-specific CTLs, and because
we did not observe the rapid emergence of CTL escape
Figure 8. Virus-specific CD81 T
cell response in the spleen of
C57BL/6 mice after primary or sec-
ondary challenge with A/Memphis/
102/72 or its variants. Splenocytes
from C57BL/6 mice isolated on day
14 after primary infection (104 PFU)
or day 10 after secondary challenge
(105 PFU) with the same virus strain
were cultured for 5 d at a density of
6 3 106 together with A/Memphis/
102/72 NP366–374 or NS2114–121 pep-
tide–pulsed (0.1 mg/ml) irradiated
(30 Gy) splenocytes (4 3 106) in 2
ml of IMDM supplemented with
10% FCS and 10 U/ml of murine
recombinant IL-2. The cytolytic ac-
tivity of restimulated splenocytes was
measured in a 51Cr-release assay us-
ing EL-4 cells pulsed with 10 mg/ml
NP366–374 (d), or NS2114–121 (h) peptide. Restimulated splenocytes were resuspended in 1 ml of medium per culture well, and serial threefold dilutions of
effector cells were performed. Results are representative of three separate experiments.1863 Price et al.
variants that would be expected from outgrowth of preex-
isting variant population after CTL pressure. However, it
remains to be determined precisely when CTL escape mu-
tations first arise in infected transgenic mice.
A vital question concerns the site of persistence of the vi-
rus before reemergence within the lung. The viruses used
in this study are pneumotropic and not reported to be ca-
pable of replication outside the respiratory tract. Further-
more, the variants retain the ability to induce cytopathic ef-
fect when grown in vitro. This suggests that rather than
true latency, virus replication is sustained by transmission
from cell to cell within the respiratory tract, albeit at levels
below the limit of detection by TCID50, until a point is
reached where inflammation and tissue damage induced by
the acute infection in the lung is resolved to a sufficient ex-
tent to allow virus to reemerge. Indeed, reduction of the
acute inflammatory response may be essential, as products
of activated CTLs and macrophages present within the
lung may be sufficient to hinder variant replication. Exper-
iments are underway to address these issues. Also of critical
importance is the issue regarding CD81 T cell effector
mechanisms in the selection of CTL escape variants. Stud-
ies on influenza pneumonia show that CD81 T cells can
function in vivo via perforin/granzyme- or Fas/FasL-medi-
ated cytolysis (53). Thus, it is of key interest to define the
contribution of these CTL effector mechanisms in selection
of CTL escape variants.
Sequence analysis of the CTL escape variants obtained in
this study reveals a remarkable diversity in mutations within
the NP gene of influenza A virus encoding the major H-2Db–
restricted CTL epitope. The mutations are nonsynonymous
and result in changes in the amino acid sequence. In this
context, it is striking that pressure exerted by a monoclonal
CTL population drives selection of variants that not only
impair T cell recognition but also binding of peptide to the
MHC molecule. The results in functional assays with variant
peptides reveal that substitutions in the anchor residue at
position 5 or 9 of NP366–374 peptide (374M®T, 370N®S,
370N®D, or 370N®T) gradually reduce the affinity of
the peptide for H-2Db molecules. As expected, the peptide
that contains alterations in TCR-exposed residues at posi-
tion 6 (371M®I) binds efficiently to H-2Db without rec-
ognition by transgenic CTLs, whereas recognition by poly-
clonal CTLs is retained. Likewise, the peptide affinity of the
variants containing the alteration 371M®V, 371M®T, or
372D®E was also tested and found to bind as well as wild-
type peptide (data not shown).
The above observations are consistent with the three-
dimensional structure of H-2Db-NP peptide complex (54),
in which the main chain of the NP366–374 peptide at posi-
tions 5 and 9 is buried in the MHC groove, and residues 4,
6, and 7 are fully accessible to solvent. It is therefore likely
that the unique in vitro pattern recognition by CTLs of tar-
get cells loaded with variant peptide (370N®S, 370N®D,
or 370N®T) is a result of H-2Db–peptide ligand density
rather than TCR ligand structure. That an excessive con-
centration of these variant peptides can induce F5 T cell
proliferation and maturation into CTLs suggests that the
signal emanating from TCR triggering on activated trans-
genic cells after engagement with MHC–variant peptide
complexes is sufficient to initiate subsequent signal trans-
duction events, resulting in cytotoxicity. In striking con-
trast, cells infected with the variant A/Mem/NP370S, A/
Mem/NP370D, A/Mem/NP370T, or A/Mem/NP374T vi-
ruses do not achieve the MHC–peptide ligand density nec-
essary for triggering T cell activation and effector function.
The data described above can be interpreted within a
model of T cell recognition based on both the total avidity
contributed by TCR affinity for MHC and peptide, and
the number of MHC–peptide complexes present at the cell
surface. Thus, under the physiological conditions of infec-
tion with the variant A/Mem/NP370S, A/Mem/NP370D,
A/Mem/NP370T, or A/Mem/NP374T viruses, the number
of MHC and NP366–374 peptide complexes generated on
the surface of APCs is not sufficient to trigger CTL activa-
tion. The virus with alteration 374M®T is particularly in-
teresting, as this variant peptide possesses relatively high af-
finity to H-2Db compared with wild-type peptide, but no
recognition of the virus occurs. One plausible explanation
for this could be that the presence of threonine at the
COOH terminus of the epitope affects peptide processing
and presentation via the endogenous proteasome/trans-
porter associated with antigen processing (TAP) transport
pathway (55). Mutations in the sequence flanking the
NP366–374 epitope that have been found to affect peptide
transport or processing (56, 57) were not observed with the
variants in this study, so this possibility can be formally
excluded. Biochemical analyses are currently underway to
test this hypothesis and define the specific factors for this
blockage.
The significance of these epitope mutations was demon-
strated in cytotoxicity and proliferation assays and by study-
ing the polyclonal CTL response elicited in immunocom-
petent mice challenged with the variants. As approximately
half of the bulk virus isolates with mutations in the anchor
residue at position 5 or 9 could not be recognized by
NP366–374 polyclonal CTLs, and no CTLs specific to NP
were detectable in infected mice, the results suggest that
these variants were biologically significant. The rest of the
virus isolates contained changes in residues (e.g., position 6
and 7) not important for TCR binding. Therefore, it was
not anticipated that changes in these residues would have a
major effect on CTL recognition in immunocompetent an-
imals, as a polyclonal CD81 CTL response should include
TCRs with a wide spectrum of fine specificity for the
NP366–374 epitope. However, epitope variants with muta-
tions at TCR contact residues can function as agonists or
antagonists of antigen-specific T cells both in vitro and in
vivo (58–60). In addition, it has been reported for HIV,
hepatitis B virus, and lymphocytic choriomeningitis virus
that the order in which a host is exposed to virus variants
can have significant effects on the outcome of infection.
Thus, after initial exposure to a particular virus strain, rein-
fection with a variant bearing mutated TCR contact sites
can boost the CTL response specific for the epitope peptide
of the earlier infection (“original sin” for CTLs), or can an-1864 CD81 CTL Escape Variants in Influenza Virus Pneumonia
tagonize (anergize) the pool of memory CTLs formed dur-
ing the primary infection. The TCR contact site change in
residue 7 of the NP366–374 epitope of 372D®E variant has
been studied in detail in our previous report (61). Infection
of F5 or F5-RAG-12/2 transgenic mice with X31 (a reas-
sortant virus bearing an alteration [372D®E] within the
NP366–374 epitope compared with A/Memphis/102/72) did
not show transgenic CTL activation, and no specific cells
were detected in the inflamed lungs. However, as the vari-
ant NP372D peptide has been described to antagonize F5
TCR activation (62, 63), we cannot exclude the possibility
that transgenic cells in mice infected with this variant
would be anergized in the draining LNs, preventing their
recruitment to the lung. Similarly, in the case of A/Mem/
NP371I, variant peptide displayed on the surface of APCs
might antagonize a substantial part of NP366–374 epitope–
specific CTLs in infected C57BL/6 mice or prevent CTL
activation in F5 transgenic mice. However, it is unclear
whether such variants could also be recognized efficiently
by a memory T cell population generated after infection
with the parental virus strain. Thus, it remains a challenge
to test in a direct manner (by virus infection) how a poly-
clonal T cell repertoire would react during an encounter
with different antigenic variants containing mutated TCR
contact sites. It is tempting to speculate that exposure of a
population to natural CTL escape variants, or selection of
such variants during an influenza outbreak, could contrib-
ute to differences of severity, duration, or rarely, fatal spread
of infection in infected individuals. Whether such variants
could be perpetuated by viral transmission from host to host
during an influenza outbreak is an open question.
Do CTL escape variants play a role in human influenza?
Host-dependent selection pressure on influenza A virus
surface antigens has been well defined, but the role of CTL
responses in genetic drift at the epidemiological level is less
clear. 2 of 11 known human influenza A virus CTL
epitopes demonstrate a surprising degree of variation,
which supports the view that even in acute infection, indi-
viduals may differ in their genetic susceptibility to viral es-
cape from CTL selection pressure (64). Experimentally de-
termined rates of virus gene/protein mutation derived from
field isolates probably are not representative of virus evolu-
tion within a single individual. Indeed, the example of per-
sistent influenza A virus infection in immunodeficiency
(65) demonstrates that coding changes can accumulate in
the NP gene as rapidly as in the HA gene in vivo. Epide-
miological studies stratified by MHC class I type or sequen-
tial isolates from acutely infected immunocompetent in-
dividuals of known class I type would be required to
demonstrate naturally occurring CTL selection pressure.
However, human CTL responses are often characterized
by a limited number of dominant epitopes and restricted
TCR usage, suggesting that at least some conditions favor-
able to CTL escape might occur in vivo. Thus, selection of
CTL escape variants may play a part in normal individuals
in a multistep process and/or under unusual conditions,
such as nonspecific immunosuppression, either alone or in
the context of T cell responses against one viral epitope
or inefficient viral clearance by neutralizing antibodies.
Whereas CTL escape variants may provide a survival bene-
fit for the virus within an individual host, the effects of
MHC polymorphism, polyclonality of the CTL response,
and the existence of subdominant epitopes would have to
be overcome for CTL escape variants to have a significant
advantage within an outbred population. Further, early
work showed that certain influenza NP–specific CTLs can
recognize viral variants in vitro, and more recently it has
been reported that CTLs cross-reactive between variants
bearing mutations at residues involved in TCR binding can
be induced infrequently in vivo (47, 48, 66). However,
more work is required to explore whether such cross-reac-
tive CTL responses can be induced in biologically signifi-
cant levels upon exposure of a host to different variant vi-
ruses, and whether this would have consequences on the
ability of the immune system to recognize and cope with
the infection. Although studies in mice have demonstrated
that influenza virus may still cleared by antibody in the ab-
sence of a CTL response, studies to examine oscillation of
CTL epitopes in the context of MHC type in sequential
virus isolates from infected humans may prove worthwhile.
Persistence of influenza virus has been described in sev-
eral immunocompromised children (65, 67). Although the
duration varies (some individuals shed virus for months),
prolonged infection characterized all the reported cases.
However, viral persistence is not an absolute requirement
for emergence and propagation of CTL escape variants.
Our observations with transgenic mice reveal that substitu-
tions within the NP366–374 epitope, which disrupts peptide
binding to H-2Db and leads to loss of recognition by poly-
clonal CTLs, can be found frequently in the context of a
dominant CTL response. The fact that the TCR repertoire
in the transgenic mice is restricted to a particular effector
cell type present at a high frequency does not necessarily
diminish the relevance of these findings to a natural infec-
tion. Thus, it has been apparent, due to advances in meth-
ods for quantitating T cells, that influenza virus-specific
CTLs can reach extremely high frequencies in normal mice
and probably in humans (43). An accelerated virus-specific
memory CTL response, for example, via immunization
could force oscillations of CTL antigens, resulting in a pro-
longed course of infection. This would have significant im-
pact on the clinical outcome of the disease.
In addition to the general interest in viral escape mecha-
nisms, the realization that an important goal in vaccination
may be the superior priming of T cells cross-reactive be-
tween different virus strains makes it necessary to under-
stand CTL recognition in the context of antigenic variation
of influenza virus. There are examples in the literature of
both prophylactic and therapeutic strategies that have led to
the selection of CTL escape variants (68, 69) mitigating the
beneficial effects of such interventions. It is a key concern
for future vaccine and/or therapy design to prevent a simi-
lar outcome.
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